News Phase 3 trial win sets up rare disease drug filing for CSL VANUGUARD trial of garadacimab in HAE sets up a pursuit of Takeda's fast-growing Takhyzro.
News Regeneron is off to CHAPLE as FDA starts pozelimab review The C5 inhibitor is vying to become the first approved drug for the ultra-rare immune disorder.
R&D Strategies in securing funding for rare disease research An outline of emerging financing strategies for rare disease research in challenging times.
News Travere undercuts key rival in rare kidney disease IgAN Filspari will launch for IgA Nepropathy at a discount to Calliditas' Tarpeyo, cleared in 2021.
News FDA gives green light to Chiesi's Lamzede Chiesi scores milestone US FDA approval for first AM enzyme replacement therapy, Lamzede.
News J&J's nipocalimab offers hope for rare foetal disorder Johnson & Johnson's nipocalimab could become the first approved treatment for a blood disorder that can lead to the death of a foetus or newborn, if positive results i
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
